BLAINJECTIONINJECTABLEPriority Review
Approved
Jul 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
TREMFYA (guselkumab) by Johnson & Johnson is interleukin-23 antagonists [moa]. Approved for interleukin-23 antagonist [epc]. First approved in 2017.
Drug data last refreshed 15h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TREMFYA (guselkumab) is a monoclonal antibody that selectively blocks interleukin-23 (IL-23), a key cytokine driving inflammatory skin diseases. It is approved for moderate-to-severe plaque psoriasis and psoriatic arthritis, with efficacy demonstrated in reducing inflammatory markers and clinical symptoms. The IL-23 antagonist mechanism represents a targeted approach to immune-mediated dermatological conditions.
$531MPart D
PeakStable
Product is at peak commercial maturity with $531M in annual Part D spending; team size and investment likely stable to slightly declining as competition intensifies.
Mechanism of Action
Interleukin-23 Antagonists
Pharmacologic Class:
Interleukin-23 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of Continued Use of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting
Started Sep 2026
35 enrolled
Crohn DiseaseColitis, Ulcerative
A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical Practice
Started Sep 2026
100 enrolled
Psoriasis
A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
Started Aug 2026
10 enrolled
PsoriasisColitis, UlcerativeCrohn Disease+1 more
Efficacy and Safety of Guselkumab in Patients With Moderate-to-Severe Ulcerative Colitis
Started Jul 2026
97 enrolled
Ulcerative Colitis (Disorder)Guselkumab
A Study of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis
Started Jun 2026
35 enrolled
Crohn DiseaseColitis, Ulcerative
Worked on TREMFYA at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.